ERBB2 and breast carcinoma: In addition, we evaluated real world effectiveness of MYL-1401O, a trastuzumab biosimilar compared to reference trastuzumab (TRZ) as measured by total pathological complete response rates (tpCR) to neoadjuvant chemotherapy patients with early HER2+ breast cancer treated in Alberta, Canada.